Company news
Novo Nordisk A/S news in 2025
Novo Nordisk A/S's news releases, calls and decks from 2025, newest first.
Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
December 31, 2025
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
December 24, 2025
FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
December 22, 2025
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
December 22, 2025
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 18, 2025
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
December 16, 2025
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
December 12, 2025
Novo Nordisk has completed its acquisition of Akero Therapeutics
December 9, 2025
New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology
December 4, 2025
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
December 3, 2025
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
November 26, 2025
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
November 25, 2025
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
November 24, 2025
9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering
November 21, 2025
Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month
November 17, 2025
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
November 14, 2025
Team Novo Nordisk announce extended partnership with Novo Nordisk for five additional years
November 14, 2025
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
November 13, 2025
Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
November 10, 2025
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
November 8, 2025
Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE
November 7, 2025
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
November 6, 2025
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
November 6, 2025
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
November 5, 2025
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
November 5, 2025
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
November 5, 2025
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
November 4, 2025
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
November 3, 2025
Metsera Receives Unsolicited Proposal from Novo Nordisk
October 30, 2025
Novo Nordisk submits proposal to acquire Metsera, Inc.
October 30, 2025
Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
October 28, 2025
Novo Holdings to make changes to its Board of Directors
October 21, 2025
The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S
October 21, 2025
Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
October 21, 2025
Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
October 21, 2025
Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
October 20, 2025
FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
October 17, 2025
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
October 15, 2025
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
October 9, 2025
Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes
September 29, 2025
Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
September 29, 2025
Calls in 2025
- Novo Nordisk (Copenhagen:NOVO B) Q3 2025 Earnings Call
Nov 5, 2025
Transcript - Novo Nordisk (Copenhagen:NOVO B) Q2 2025 Earnings Call
Aug 6, 2025
Transcript - Novo Nordisk (Copenhagen:NOVO B) Q1 2025 Earnings Call
May 7, 2025
Transcript - Novo Nordisk (Copenhagen:NOVO B) Q4 2024 Earnings Call
Feb 5, 2025
Transcript
Decks in 2025
- 67th ASH Annual Meeting and Exposition 2025
Conference · 17 slides · December 2025
- Shareholder Meeting (November 2025)
Shareholder meeting · 20 slides · Nov 14, 2025
- Q3 2025 Earnings Presentation
Earnings · 138 slides · Nov 5, 2025
- Merger or Acquisition (October 2025)
Merger or acquisition · 8 slides · Oct 9, 2025
- Technical Presentation (September 2025)
Technical · 5 slides · Sep 15, 2025
- European Society of Cardiology (ESC) Congress together with World Congress of Cardiology 2 (August 2025)
Conference · 15 slides · Aug 31, 2025
- H1 2025 Earnings Presentation
Earnings · 180 slides · Aug 6, 2025
- Investor Day (June 2025)
Investor day · 58 slides · Jun 22, 2025
- Q1 2025 Earnings Presentation
Earnings · 173 slides · May 7, 2025
- Shareholder Meeting (March 2025)
Shareholder meeting · 53 slides · Mar 27, 2025
- Shareholder Meeting (March 2025)
Shareholder meeting · 53 slides · Mar 27, 2025
- Shareholder Meeting (February 2025)
Shareholder meeting · 18 slides · Feb 27, 2025
- FY2024 Earnings Presentation
Earnings · 164 slides · Feb 5, 2025
- Technical Presentation (2025)
Technical · 19 slides · 2025
- Technical Presentation (2025)
Technical · 15 slides · 2025